Valuation Metrics Indicate Premium Pricing
As of 26 Nov 2025, SMS Pharma’s price-to-earnings (PE) ratio stands at 35.8, significantly higher than the broader market average and many of its pharmaceutical peers. This elevated PE ratio signals that investors are willing to pay a substantial premium for the company’s earnings, reflecting expectations of sustained growth or superior profitability. The price-to-book (P/B) ratio of 4.14 further underscores the premium valuation, indicating that the stock is priced well above its net asset value.
Enterprise value multiples also point to an expensive valuation. The EV to EBIT ratio of 26.0 and EV to EBITDA of 20.1 are notably higher than several competitors, suggesting that the market values SMS Pharma’s operating earnings mor...
Read More












